caa a22 4500 465805388 CHVBK 20180323112102.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF03350694 doi (NATIONALLICENCE)springer-10.1007/BF03350694 Osteocalcin levels in patients with microprolactinoma before and during medical treatment [Elektronische Daten] [A. Sartorio, A. Conti, B. Ambrosi, M. Muratori, F. Morabito, G. Faglia] Osteocalcin (OC) concentration, a specific index of bone formation, was measured in 29 female patients with microprolactinoma (serum prolactin, PRL: 105 ± 10.9 ng/ml; mean ± SE). Mean OC levels were significantly lower than in controls (1.7 ± 0.2 vs 5.1 ± 0.3 ng/ml; p < 0.001), being below the normal range in 28 out of 29 patients. All patients were treated with dopaminergic agents (dihydroergocriptine, bromocriptine or cabergoline). After treatment mean serum PRL levels were significantly reduced (12 ± 3.1 ng/ml; p < 0.001), a full normalization being obtained in 26 patients. There were no significant differences in both basal and after treatment PRL levels among patients treated with different drugs, although a greater PRL decrease was induced by cabergo-line. Serum OC levels significantly increased after 12 month therapy (4.7 ± 0.6 ng/ml, p < 0.001), a normal concentration being reached in 14 of 29 cases. During treatment there were no significant differences in serum estradiol and PRL concentrations between patients who normalized or not their OC levels, while the reduction in PRL levels with respect to baseline was more pronounced in the former group. The absolute increase in OC levels positively correlated with serum PRL decrements (p < 0.01). It is noteworthy that serum OC normalized in 1/10 patients during dihydroergocriptine, 3/8 during bromocriptine and 10/11 during cabergoline. Four patients, previously treated with dihydroergocriptine and bromocriptine without normalizing OC and PRL levels, underwent a second course of therapy with cabergoline and then normalized OC concentrations. In conclusion, these preliminary data show that i) OC levels are reduced in women with microprolactinoma, ii) after successful treatment of hyperprolactinemia a recovery of osteoblastic activity frequently occurs. Further investigations on the actions of dopaminergic drugs are needed, in view of their different effects on OC concentrations. Tresented in part at the 7th International Congress on calciotropic hormones and calcium metabolism, Salsomaggiore, Italy, October 1988. Italian Society of Endocrinology (SIE), 1990 Osteocalcin nationallicence prolactinoma nationallicence prolactin nationallicence bone formation nationallicence dopaminergic agents nationallicence Sartorio A. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut Conti A. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut Ambrosi B. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut Muratori M. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut Morabito F. Centro Auxologico Italiano, via L Ariosto 13, 20145, Milano, Italy aut Faglia G. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut Journal of Endocrinological Investigation Springer International Publishing 13/5(1990-05-01), 419-422 0391-4097 13:5<419 1990 13 40618 https://doi.org/10.1007/BF03350694 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF03350694 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sartorio A. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut NATIONALLICENCE 700 1- Conti A. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut NATIONALLICENCE 700 1- Ambrosi B. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut NATIONALLICENCE 700 1- Muratori M. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut NATIONALLICENCE 700 1- Morabito F. Centro Auxologico Italiano, via L Ariosto 13, 20145, Milano, Italy aut NATIONALLICENCE 700 1- Faglia G. Istituto di Scienze Endocrine, Università di Milano, Ospedale Policlinico, Pad. Sacco, Via F. Sforza 35, 20122, Milano, Italy aut NATIONALLICENCE 773 0- Journal of Endocrinological Investigation Springer International Publishing 13/5(1990-05-01), 419-422 0391-4097 13:5<419 1990 13 40618 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer